XML 59 R48.htm IDEA: XBRL DOCUMENT v3.21.2
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Reconciliation of revenue from segments to consolidated
The following tables present our segment information for the three and nine months ended September 30, 2021 and 2020 (in thousands). Prior-year segment information (including segments total Adjusted EBITDA) has been restated to conform to the reporting structure change described in Note 1.

Evolent Health ServicesClinical SolutionsIntersegment
Eliminations		Subtotal
Corporate (1)
Consolidated
Revenue
For the Three Months Ended September 30, 2021
Transformation services$2,075 $— $— $2,075 $— $2,075 
Platform and operations services61,240 159,614 (458)220,396 — 220,396 
Total revenue$63,315 $159,614 $(458)$222,471 $— $222,471 
For the Three Months Ended September 30, 2020
Transformation services$4,807 $— $— $4,807 $— $4,807 
Platform and operations services95,361 140,071 (667)234,765 — 234,765 
Total revenue$100,168 $140,071 $(667)$239,572 $— $239,572 
Evolent Health ServicesClinical SolutionsSubtotal
Corporate (1)
Segments Total
For the Three Months Ended September 30, 2021
Adjusted EBITDA$(3,353)$23,883 $20,530 $(6,765)$13,765 
For the Three Months Ended September 30, 2020
Adjusted EBITDA$24,645 $(974)$23,671 $(9,888)$13,783 

Evolent Health ServicesClinical SolutionsIntersegment
Eliminations		Subtotal
Corporate (1)
Consolidated
Revenue
For the Nine Months Ended September 30, 2021
Transformation services$4,984 $— $— $4,984 $— $4,984 
Platform and operations services218,940 437,031 (1,356)654,615 — 654,615 
Total revenue$223,924 $437,031 $(1,356)$659,599 $— $659,599 
For the Nine Months Ended September 30, 2020
Transformation services$10,800 $— $— $10,800 $— $10,800 
Platform and operations services273,583 395,723 (2,003)667,303 — 667,303 
Total revenue$284,383 $395,723 $(2,003)$678,103 $— $678,103 
Evolent Health ServicesClinical SolutionsSubtotal
Corporate (1)
Segments Total
For the Nine Months Ended September 30, 2021
Adjusted EBITDA$9,120 $53,456 $62,576 $(20,558)$42,018 
For the Nine Months Ended September 30, 2020
Adjusted EBITDA$36,361 $18,269 $54,630 $(26,452)$28,178 
————————
(1)Corporate includes various finance, human resources, legal, executive, and other corporate infrastructure expenses.
Reconciliation of Adjusted EBITDA to net loss
The following table presents our reconciliation of consolidated segments total Adjusted EBITDA to net loss attributable to common shareholders of Evolent Health, Inc. for the three and nine months ended September 30, 2021 and 2020 (in thousands):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2021202020212020
Net loss attributable to common shareholders of Evolent Health, Inc.$(13,040)$(37,348)$(31,954)$(319,621)
Less:
Interest income120 1,159 311 2,634 
Interest expense(6,367)(7,416)(18,978)(19,987)
(Provision) benefit for income taxes(234)(503)(936)3,131 
Depreciation and amortization expenses(14,859)(14,534)(44,962)(46,130)
Equity method investment impairment— — — (47,133)
Gain on transfer of membership— — 22,969 — 
Loss on repayment of debt, net— — (19,158)— 
Loss on extinguishment of debt— (4,789)— (4,789)
Goodwill impairment— — — (215,100)
Gain from equity method investees63 (13,717)12,725 11,014 
Loss on disposal of assets— — — (6,447)
Change in fair value of contingent consideration and indemnification asset225 (2,570)819 492 
Net loss attributable to non-controlling interests— 822 — 822 
Other income (expense), net(41)(110)(73)174 
Repositioning costs— — (6,043)— 
Stock-based compensation expense(4,395)(3,164)(11,754)(10,375)
Severance costs— (1,757)(52)(7,890)
Amortization of contract cost assets(110)(2,610)(433)(3,817)
Strategy and shareholder advisory expenses— — (6,513)— 
Acquisition costs(1,207)(807)(3,277)(1,490)
Gain (loss) from discontinued operations (1)
— (1,135)1,383 (2,908)
Adjusted EBITDA$13,765 $13,783 $42,018 $28,178 
————————
(1)Includes $1.9 million gain on disposal of discontinued operations for the nine months ended September 30, 2021.